Contact Information

Biography

Dr. Very is currently the Director of the M.S. Degree Program in Biotechnology.  He has held executive leadership positions at Naviter Bioanalytics, LLC (Founder, CEO); Helomics Corporation (VP, Scientific Strategy, Technology, and Research);  Ancera, Inc., (VP, Research and Assay Development); and The Institute for Bioanalytics, LLC (VP, Immunology and Assay Development).  Additionally, he served as a Senior Research Scientist at Bayer Diagnostics, and as supervisor of the BL-2 and BL-3 laboratories at the U.S. Army Medical Research Unit in the Republic of Korea.  

With over thirty years of diagnostic, clinical laboratory, and pharmaceutical assay development experience in oncology, infectious disease, and metabolic disease, Dr. Very is a frequently invited speaker at national and international scientific symposia discussing topics including the advances in personalized medicine in oncology, the clinical utility of serum biomarkers in the diagnosis and management of disease, and the future of the in vitro diagnostic industry. 

Education

  • Ph.D., Microbiology/Immunology, Boston University
  • M.S., Biology, University of Texas at San Antonio
  • B.S, Biology, University of Notre Dame

Research Interests

  • Cancer Biology and Immunology
  • Autoimmunity
  • Personalized medicine in oncology
  • Development, qualification, and validation of quantitative analytical methods for biomarkers

School

About

  1. Campbell, N.J., Very, D.L., Jr., Reitze, N.J., Gilkey, A.W., Swackhammer, R.L., Jr., Dray, C.M., Skoff, B.S., and Thiel, K.J.  “Ex vivo Liquid Biopsy”.  U. S. Patent Application Number 62/306,867.  Provisional application filed March 11, 2016.  Non-provisional application filed March 10, 2017.
  2. Haigh, W.B., and Very, D.L., Jr.  "Methods for the Early Diagnosis of Kidney Disease".  U.S. Patent Number 9,000,143 B2.  Date of Issue:  April 7, 2015
  3. Haigh, W.B., Guralski, D.M., Arrigo, L.M., Letsinger, J., Clarke, M., MacIsaac, R.J., Jerums, G., and Very, D.L.  Development of a Novel Polyclonal Antibody-Based Immunoassay for the Quantitation of Non-Albumin Urinary Proteins.  The Open Clinical Chemistry Journal 6:  1-12 (2013).
  4. Haigh, W.B., and Very, D.L., Jr.  "Methods for the Early Diagnosis of Kidney Disease".  International Patent Application, PCT Serial No. WO 2008/141285 A2.  Filed May 11, 2007.
  5. Cheli, C.D., Morris, D.L., Kish, L., Goldblatt, J., Neaman, I., Allard, W.J., Yeung, K.K., Wu, A.H.B., Moore, R., Chan, D.W., Fritsche, H.A., Schwartz, M.K., and Very, Jr., D.L.  Bayer Immuno 1 CA 15-3 Assay:  A Highly Precise and Fully-Automated Immunoassay for Longitudinal Monitoring of CA 15-3 Assay Values.  Clinical Chemistry 44:  765 (1998).
  6. Morris D.L., Dillon, P.W., Very, D.L., Ng, P., Kish, L., Goldblatt, J.L., Bruzek, D.J., Chan, D.W., Ahmed, M.S., Witek, D., Fritsche, H.A., Smith, C., Schwartz, D., Schwartz, M.K., Noteboom, J.L., Vessella, R.L., Yeung, K.K, and Allard, W.J.  Bayer Immuno 1 PSA Assay:  An Automated, Ultrasensitive Method to Quantitate Total PSA in Serum.  Journal of Clinical Lab Analysis 12: 65 (1998).  
  7. Very, Jr., D.L., Kish, L., Arrigo, L., Neaman, I., Goldblatt, J., Allard, W.J., and Yeung, K. K.  The Technicon Immuno 1® CA 125 II™ Assay:  A Rapid, Precise, and Fully-Automated Immunoassay for the Quantitation of Serum CA 125 II™ Assay Values.   Proceedings of the VI International Symposium on the Biology and Clinical Usefulness of Tumor Markers.   Tumor Biology 16 (suppl. 1) 1996.
  8. Very, Jr., D.L., Arrigo, L., Kish, L., Zhou, Z., Ng, P., Carpenter, W., Allard, W.J., and Yeung, K. K.  Clinical Performance Evaluation of a Fully-Automated Immunoassay for the Quantitation of Serum CA 15-3™ Assay Values on the Technicon Immuno 1® Analyzer.  Proceedings of the VI International Symposium on the Biology and Clinical Usefulness of Tumor Markers.  Tumor Biology 16 (Suppl.1) 1996.
  9. Zhou, Z., Ng, P. C., Very, D. L., Jr., Allard, W. J., and Yeung, K. K.  The Technicon Immuno 1® PSA Assay Measures Both Free and Alpha-1-Antichymotrypsin-Complexed Prostate Specific Antigen on an Equal Molar Basis.  Journal of Clinical Laboratory Analysis 10:  155-159 (1996).
  10. Very, D. L., Panka, D. J., Weissman, D., Wysocki, L., Manser, T., and Marshak-Rothstein, A.  Lack of Connectivity Between the Induced and Autoimmune Repertoires of lpr/lpr Mice.  Immunology 80:  518 (1993). 
  • STEMup; Educate, Graduate, Innovate Pittsburgh, Richard King Mellon Foundation; 2023
  • Preliminary Clinical Utility Assessment of a Novel Competitive Immunoassay in the Detection of Proteinuria in Ghanaian Patients with Sickle Cell Disease, Loogman Faculty Research Grant, Duquesne University, 2022
  • BTGY 510  Independent Study
  • BTGY 515 Current Topics in Biotechology
  • BTGY 516  Cellular & Molecular Biology
  • BTGY 679  Research/Internship